Welcome to our dedicated page for Iveda Solutions SEC filings (Ticker: IVDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Iveda Solutions, Inc. filings document the company's public-company reporting as a Delaware corporation focused on AI video surveillance, smart city technologies, and IoT platforms. Registration statements and amendments describe securities offerings, capital structure, operating and financial results, and risk disclosures tied to the company's technology business.
Current reports cover material events including Nasdaq continued-listing notices, stockholders' equity compliance, minimum bid-price matters, and registered securities consisting of common stock and common stock purchase warrants. Proxy materials document annual meeting matters such as director elections, auditor ratification, shareholder voting mechanics, and governance procedures.
Iveda Solutions, Inc. (IVDA) reports that Nasdaq has granted an additional 180‑day grace period, through March 1, 2027, to regain compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2). The extension follows Iveda meeting all other applicable initial listing standards, including the market value of publicly held shares.
To regain compliance, Iveda’s common stock must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during this new period, with Nasdaq able to require a longer span. Iveda states it will monitor its share price and other listing standards and may consider a reverse stock split if appropriate, but has not decided to implement one. The company cautions there is no assurance it will regain or maintain compliance; failure to do so by March 1, 2027 could result in delisting, subject to any appeal.
Iveda Solutions, Inc. reported lower revenue but improved gross profit for the six months ended June 30, 2026. Total revenue was $2.30 million, down from $3.00 million a year earlier, driven mainly by reduced equipment sales in both the U.S. distributor channel and Taiwan government contracts due to delivery timing.
Gross profit increased to $0.93 million from $0.73 million, reflecting a higher mix of higher-margin contracts in both regions. The company recorded a net loss of $1.33 million, similar to the prior-year period. Cash, restricted cash and cash equivalents totaled $4.83 million, and management expects this to fund the current operating plan for at least twelve months from the financial statement issuance date.
Iveda strengthened its capital position through a February 2026 public offering and warrant exercises, issuing over 5.7 million new common shares and new warrants, and ending the period with 12,519,027 shares outstanding. Revenue remains highly concentrated, with 72% of first-half 2026 revenue coming from three Taiwan customers. Management disclosed that disclosure controls and procedures and internal control over financial reporting were not effective as of June 30, 2026, and the company continues to report recurring operating losses while pursuing growth in AI-driven smart city and IoT solutions.
Iveda Solutions, Inc. reported that investment entities Lind Global Fund III LP and Lind Global Partners III LLC, together with Jeff Easton, beneficially own common stock equivalents representing 1,286,794 shares, equal to 9.99% of the company’s common stock. This position arises from 1,714,286 warrants to purchase common shares.
The warrants include a conversion limitation that caps exercisability so the holders cannot beneficially own more than 9.99% of Iveda’s common stock at any time, which restricts how many shares can be treated as currently beneficially owned.
Iveda Solutions reported Q1 2026 revenue of $1.49 million, up slightly from $1.47 million a year earlier, driven mainly by higher Taiwan government project sales. Gross profit rose to $0.50 million, improving margin as cost of revenue fell. The company still posted a net loss of $0.53 million, narrower than the prior-year loss of $0.79 million, and used $0.9 million of cash in operations.
During the quarter Iveda raised net proceeds of about $1.6 million through a February 2026 equity offering, doubling common shares outstanding to 11.6 million and ending the period with $5.7 million in cash. Management concluded this cash should fund the operating plan for at least 12 months, though the company continues to carry an accumulated deficit and relies heavily on a few large Taiwan customers. Internal control over financial reporting and disclosure controls were assessed as not effective due to material weaknesses, which management is working to remediate.
Iveda Solutions disclosure of beneficial ownership by Iroquois Capital Management, Richard Abbe and Kimberly Page. The filing reports each Reporting Person as beneficially owning 585,068 shares of Common Stock, reflecting shares issuable upon exercise of warrants that are subject to 4.99% Beneficial Ownership Blockers. The Form 10-K shows 11,139,740 shares outstanding as of March 15, 2026, and the warrants described are exercisable for up to 1,000,000 and 428,572 shares respectively but cannot be exercised beyond the 4.99% limit.
Iveda Solutions, Inc. files a Prospectus Supplement No. 14 dated April 1, 2026 that updates its August 30, 2022 prospectus to include the company’s Annual Report on Form 10-K for the period ended December 31, 2025 (filed March 31, 2026). The supplement covers registration language for 138,759 shares of common stock, warrants to purchase up to 411,185 shares of common stock at an exercise price of $11.20, and pre-funded warrants to purchase up to 273,685 shares of common stock, and incorporates the Form 10-K by reference.
The supplement is qualified by reference to the underlying prospectus and is intended to be read together with it, including its "Risk Factors" section. This document does not itself change offering terms; it adds the Form 10-K information to the existing prospectus package.
Iveda Solutions, Inc. files a Prospectus Supplement No. 14 to the March 31, 2022 prospectus to include its Form 10-K and to cover warrants to purchase 235,625 shares of common stock at a strike price of $34.00 per share held by stockholders identified in the prospectus.
Iveda Solutions, Inc. registers primary securities for sale. The prospectus supplement registers 5,259,999 shares of Common Stock, up to 5,714,286 Series X Warrants to purchase up to 11,428,572 shares of Common Stock, and up to 400,000 Placement Agent Warrants to purchase up to 400,000 shares. The supplement incorporates the company's Form 10-K for the period ended December 31, 2025 and updates the Prospectus effective February 9, 2026.
Iveda Solutions, Inc., now a Delaware corporation listed on Nasdaq, reports continued operating losses while positioning itself as an AI-driven smart city and IoT platform provider. For the year ended December 31, 2025, it recorded a net loss of about $3.2 million, following a $4.0 million loss in 2024, and has accumulated losses of roughly $56 million.
The company depends heavily on its Taiwan subsidiary, which generated 85% of 2025 revenue and 87% of 2024 revenue, and on a small number of large customers; four customers made up 63% of 2025 revenue. Iveda offers AI video analytics (IvedaAI), IoT platforms (Cerebro), smart power solutions, smart poles, drones, health and elder-care devices, and industrial monitoring tools.
As of March 15, 2026, Iveda had 11,139,740 shares of common stock outstanding and significant U.S. net operating loss carryforwards of about $40.0 million federal and $11.0 million state. The company highlights risks from ongoing losses, reliance on key personnel, geopolitical uncertainty around Taiwan, cybersecurity gaps, and potential Nasdaq listing compliance issues.
Iveda Solutions, Inc. has been notified by Nasdaq that its common stock no longer meets the exchange’s minimum bid price requirement of $1 per share, after trading below that level for 30 consecutive business days. The notice does not immediately affect the stock’s Nasdaq listing.
The company has 180 calendar days, until September 2, 2026, to regain compliance. Nasdaq will deem the requirement met if the closing bid price is at least $1 for a minimum of ten consecutive business days during this period. If compliance is not restored or other listing rules are breached, Nasdaq may move to delist the shares, although Iveda could appeal any delisting determination to a Nasdaq Hearings Panel.